Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

Dyslipidemia is an important risk factor for cardiovascular disease (CVD) and atherosclerosis. When dyslipidemia coincides with other metabolic disorders such as obesity, hypertension, and glucose intolerance, defined as the metabolic syndrome (MS), individuals present an elevated risk to develop type 2 diabetes (T2D) as well as CVD. Because the MS epidemic represents a growing public health problem worldwide, the development of therapies remains a major challenge. Alterations of bile acid pool regulation in T2D have revealed a link between bile acid and metabolic homeostasis. The bile acid receptors farnesoid X receptor (FXR) and TGR5 both regulate lipid, glucose, and energy metabolism, rendering them potential pharmacological targets for MS therapy. This review discusses the mechanisms of metabolic regulation by FXR and TGR5 and the utility relevance of natural and synthetic modulators of FXR and TGR5 activity, including bile acid sequestrants, in the treatment of the MS.

[1]  R. Dowling,et al.  Gallstone dissolution in man using chenodeoxycholic acid. , 1972, Lancet.

[2]  S. Erill.  Letter: Cycloserine and tuberulous meningitis. , 1973, Lancet.

[3]  P. Nestel,et al.  Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. , 1974, Lancet.

[4]  M. Lawson,et al.  ZINC AND DIODOQUIN IN ACRODERMATITIS ENTEROPATHICA , 1975, The Lancet.

[5]  J. R. Evans,et al.  Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. , 1978, British journal of clinical pharmacology.

[6]  H. G. Morgan,et al.  The effects of cholestyramine on high density lipoprotein metabolism. , 1979, Atherosclerosis.

[7]  J. Lachin,et al.  Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. , 1981, Annals of internal medicine.

[8]  S. Grundy,et al.  Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. , 1982, Metabolism: clinical and experimental.

[9]  K. von Bergmann,et al.  Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. , 1982, Scandinavian journal of gastroenterology.

[10]  K. Setchell,et al.  General methods for the analysis of metabolic profiles of bile acids and related compounds in feces. , 1983, Journal of lipid research.

[11]  C. E. Becker.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[12]  Roger A. Renfrew,et al.  Lipid Research Clinics Program. , 1984, JAMA.

[13]  R. Diasio,et al.  Identification of bile acid coenzyme A synthetase in rat kidney. , 1993, Journal of lipid research.

[14]  A. Cooper,et al.  Regulation of cholesterol 7 alpha-hydroxylase gene expression in Hep-G2 cells. Effect of serum, bile salts, and coordinate and noncoordinate regulation with other sterol-responsive genes. , 1994, The Journal of biological chemistry.

[15]  C. Falany,et al.  Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. , 1994, The Journal of biological chemistry.

[16]  S. Grundy,et al.  Cholestyramine Therapy for Dyslipidemia in NonInsulin-dependent Diabetes Mellitus: A Short-Term, Double-Blind, Crossover Trial , 1994, Annals of Internal Medicine.

[17]  R. Morishita,et al.  The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Barter,et al.  Remodelling of high density lipoproteins by plasma factors. , 1999, Atherosclerosis.

[19]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[20]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[21]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.

[22]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[23]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[24]  D. Moore,et al.  The Farnesoid X-activated Receptor Mediates Bile Acid Activation of Phospholipid Transfer Protein Gene Expression* , 2000, The Journal of Biological Chemistry.

[25]  T. Willson,et al.  Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. , 2001, Molecular endocrinology.

[26]  R. Evans,et al.  An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  N. Mitro,et al.  The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. , 2001, The Journal of biological chemistry.

[28]  J. Auwerx,et al.  The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. , 2002, Molecular endocrinology.

[29]  J. Dallongeville,et al.  Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. , 2002, The Journal of clinical investigation.

[30]  H. Fujii,et al.  Bile Acids Enhance Low Density Lipoprotein Receptor Gene Expression via a MAPK Cascade-mediated Stabilization of mRNA* , 2002, The Journal of Biological Chemistry.

[31]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[32]  Takao Nakamura,et al.  Identification of membrane-type receptor for bile acids (M-BAR). , 2002, Biochemical and biophysical research communications.

[33]  P. Young,et al.  Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. , 2002, Gene.

[34]  X. Hu,et al.  The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. , 2002, Molecular endocrinology.

[35]  Celeste Eng,et al.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. , 2002, The Journal of clinical investigation.

[36]  D. Mangelsdorf,et al.  A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR , 2002, Science.

[37]  Roberto Pellicciari,et al.  Structural basis for bile acid binding and activation of the nuclear receptor FXR. , 2003, Molecular cell.

[38]  R. Evans,et al.  Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. , 2003, Organic & biomolecular chemistry.

[39]  Giovanni Galli,et al.  Coordinated Control of Cholesterol Catabolism to Bile Acids and of Gluconeogenesis via a Novel Mechanism of Transcription Regulation Linked to the Fasted-to-fed Cycle* , 2003, Journal of Biological Chemistry.

[40]  Grace Guo,et al.  The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis* , 2003, The Journal of Biological Chemistry.

[41]  D. Rader,et al.  Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. , 2003, JAMA.

[42]  Masataka Harada,et al.  A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.

[43]  Jasmine Chen,et al.  Identification of Gene-selective Modulators of the Bile Acid Receptor FXR* , 2003, The Journal of Biological Chemistry.

[44]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[45]  S. Kliewer,et al.  Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. , 2003, Genes & development.

[46]  S. Tazuma,et al.  Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[47]  R. Evans,et al.  Discovery and Optimization of Non‐steroidal FXR Agonists from Natural Product‐Like Libraries. , 2003 .

[48]  F. Gonzalez,et al.  Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. , 2003, Gastroenterology.

[49]  S. Wright,et al.  Guggulsterone Is a Farnesoid X Receptor Antagonist in Coactivator Association Assays but Acts to Enhance Transcription of Bile Salt Export Pump* , 2003, The Journal of Biological Chemistry.

[50]  R. Sato,et al.  Bile Acid Reduces the Secretion of Very Low Density Lipoprotein by Repressing Microsomal Triglyceride Transfer Protein Gene Expression Mediated by Hepatocyte Nuclear Factor-4* , 2004, Journal of Biological Chemistry.

[51]  A. Fukamizu,et al.  Bile Acids Regulate Gluconeogenic Gene Expression via Small Heterodimer Partner-mediated Repression of Hepatocyte Nuclear Factor 4 and Foxo1* , 2004, Journal of Biological Chemistry.

[52]  A. Bookout,et al.  Prevention of cholesterol gallstone disease by FXR agonists in a mouse model , 2004, Nature Medicine.

[53]  D. Hum,et al.  The farnesoid X receptor induces very low density lipoprotein receptor gene expression , 2004, FEBS letters.

[54]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[55]  Ram B. Singh,et al.  Hypolipidemic and antioxidant effects of commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia , 1994, Cardiovascular Drugs and Therapy.

[56]  J. Chiang.  Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. , 2004, Journal of hepatology.

[57]  J. Bisi,et al.  Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. , 2004, Molecular endocrinology.

[58]  B. Staels,et al.  Glucose regulates the expression of the farnesoid X receptor in liver. , 2004, Diabetes.

[59]  T. Warner,et al.  Expression and activation of the farnesoid X receptor in the vasculature. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Morelli,et al.  The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. , 2004, Gastroenterology.

[61]  R. Savkur,et al.  Regulation of carbohydrate metabolism by the farnesoid X receptor. , 2005, Endocrinology.

[62]  G. Salen,et al.  Bile acid biosynthesis , 1974, The American Journal of Digestive Diseases.

[63]  Folkert Kuipers,et al.  The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition* , 2005, Journal of Biological Chemistry.

[64]  G. Tsujimoto,et al.  Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. , 2005, Biochemical and biophysical research communications.

[65]  T. Willson,et al.  Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis , 2005, Journal of Pharmacology and Experimental Therapeutics.

[66]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[67]  C. J. Sinal,et al.  Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice Published, JLR Papers in Press, September 26, 2005. DOI 10.1194/jlr.M500390-JLR200 , 2005, Journal of Lipid Research.

[68]  K. Houck,et al.  The Hypolipidemic Natural Product Guggulsterone Is a Promiscuous Steroid Receptor Ligand , 2005, Molecular Pharmacology.

[69]  Ke Ma,et al.  Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.

[70]  S. Fiorucci,et al.  The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo , 2006, Molecular Pharmacology.

[71]  B. Brewer,et al.  Effects of FXR in foam-cell formation and atherosclerosis development. , 2006, Biochimica et biophysica acta.

[72]  G. Shulman,et al.  Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. , 2006, American journal of physiology. Endocrinology and metabolism.

[73]  Simon C Watkins,et al.  Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells , 2006, Circulation research.

[74]  S. Kliewer,et al.  Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[75]  H. Miyoshi,et al.  Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. , 2006, The Journal of endocrinology.

[76]  S. Fiorucci,et al.  Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. , 2006, Journal of medicinal chemistry.

[77]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[78]  Dae-Joong Kang,et al.  Bile salt biotransformations by human intestinal bacteria Published, JLR Papers in Press, November 18, 2005. , 2006, Journal of Lipid Research.

[79]  W. Insull.  Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review , 2006, Southern medical journal.

[80]  Folkert Kuipers,et al.  The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* , 2006, Journal of Biological Chemistry.

[81]  P. Edwards,et al.  FXR Deficiency Causes Reduced Atherosclerosis in Ldlr−/− Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[82]  Timothy M Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[83]  S. Li,et al.  Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation* , 2006, Journal of Biological Chemistry.

[84]  P. Jones,et al.  Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans. , 2006, Translational research : the journal of laboratory and clinical medicine.

[85]  R. Rosenson.  Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. , 2006, Atherosclerosis.

[86]  J. Mehta,et al.  Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. , 2006, American journal of physiology. Heart and circulatory physiology.

[87]  S. Schwartz,et al.  Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. , 2007, Clinical therapeutics.

[88]  J. Auwerx,et al.  Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. , 2007, Biochemical and biophysical research communications.

[89]  H. Nakano,et al.  Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. , 2007, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[90]  G. King,et al.  Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[91]  T. Warner,et al.  Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[92]  S. Kliewer,et al.  Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine Published, JLR Papers in Press, August 24, 2007. , 2007, Journal of Lipid Research.

[93]  D. Moore,et al.  The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. , 2007, Molecular endocrinology.

[94]  E. Schiffrin,et al.  Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients , 2007, Hypertension.

[95]  T. Yamakawa,et al.  Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. , 2007, Endocrine journal.

[96]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[97]  S. Sahlin,et al.  Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. , 2007, Biochemical and biophysical research communications.

[98]  S. Kliewer,et al.  FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption Published, JLR Papers in Press, September 6, 2007. , 2007, Journal of Lipid Research.

[99]  M. Krempf,et al.  Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes , 2008, FEBS letters.

[100]  J. W. Becker,et al.  Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation , 2008, Proceedings of the National Academy of Sciences.

[101]  F. He,et al.  FXR-mediated regulation of eNOS expression in vascular endothelial cells. , 2008, Cardiovascular research.

[102]  R. Goldberg,et al.  Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. , 2008, Archives of internal medicine.

[103]  D. Hum,et al.  Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. , 2008, Molecular endocrinology.

[104]  D. Häussinger,et al.  Expression and function of the bile acid receptor TGR5 in Kupffer cells. , 2008, Biochemical and biophysical research communications.

[105]  T. Billiar,et al.  FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. , 2008, Cardiovascular research.

[106]  R. Goldberg,et al.  Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. , 2008, Archives of internal medicine.

[107]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. , 2008, Bioorganic & medicinal chemistry letters.

[108]  J. Auwerx,et al.  Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. , 2008, Journal of medicinal chemistry.

[109]  J. Rosenstock,et al.  Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy , 2008, Diabetes Care.

[110]  Johan Auwerx,et al.  Targeting bile-acid signalling for metabolic diseases , 2008, Nature Reviews Drug Discovery.

[111]  D. Moore,et al.  Dietary procyanidins lower triglyceride levels signaling through the nuclear receptor small heterodimer partner. , 2008, Molecular nutrition & food research.

[112]  C. Huard,et al.  A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[113]  R. Rosenson,et al.  Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. , 2009, Atherosclerosis.

[114]  T. Willson,et al.  Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia* , 2009, The Journal of Biological Chemistry.

[115]  J. Auwerx,et al.  TGR5-mediated bile acid sensing controls glucose homeostasis. , 2009, Cell metabolism.

[116]  M. Evans,et al.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice Published, JLR Papers in Press, January 27, 2009. , 2009, Journal of Lipid Research.

[117]  J. Auwerx,et al.  Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. , 2009, Journal of medicinal chemistry.

[118]  E. Distrutti,et al.  Antiatherosclerotic effect of farnesoid X receptor. , 2009, American journal of physiology. Heart and circulatory physiology.

[119]  J. Holst,et al.  Preliminary report: genetic variation within the GPBAR1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus. , 2009, Metabolism: clinical and experimental.

[120]  T. Murata,et al.  Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle. , 2009, American journal of physiology. Heart and circulatory physiology.

[121]  M. Taniai,et al.  Treatment of nonalcoholic steatohepatitis with colestimide , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[122]  Stefan Westin,et al.  Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). , 2009, Journal of medicinal chemistry.

[123]  O. Tawfik,et al.  Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet , 2009, Journal of Pharmacology and Experimental Therapeutics.

[124]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[125]  Songwen Zhang,et al.  Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[126]  A. Grefhorst,et al.  An Increased Flux through the Glucose 6-Phosphate Pool in Enterocytes Delays Glucose Absorption in Fxr–/– Mice* , 2009, Journal of Biological Chemistry.

[127]  Youhua Liu,et al.  Coordinated Regulation of Dimethylarginine Dimethylaminohydrolase-1 and Cationic Amino Acid Transporter-1 by Farnesoid X Receptor in Mouse Liver and Kidney and Its Implication in the Control of Blood Levels of Asymmetric Dimethylarginine , 2009, Journal of Pharmacology and Experimental Therapeutics.

[128]  D. Moore,et al.  Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner. , 2009, Molecular nutrition & food research.

[129]  D. Häussinger,et al.  The membrane‐bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders , 2009, Hepatology.

[130]  K. Evans,et al.  Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. , 2009, Journal of medicinal chemistry.

[131]  T. Veenstra,et al.  FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. , 2009, Cell metabolism.

[132]  L. Adorini,et al.  Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist , 2010, Molecular Pharmacology.

[133]  G. Farrell,et al.  A fresh look at NASH pathogenesis. Part 1: The metabolic movers , 2010, Journal of gastroenterology and hepatology.

[134]  F. Kuipers,et al.  Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism , 2010, Hepatology.

[135]  U. Deuschle,et al.  Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. , 2010, Bioorganic & medicinal chemistry letters.

[136]  S. Fiorucci,et al.  The bile acid sensor FXR regulates insulin transcription and secretion. , 2010, Biochimica et biophysica acta.

[137]  S. Fiorucci,et al.  FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats[S] , 2010, Journal of Lipid Research.

[138]  B. Staels,et al.  The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-γ and Interfering with the Wnt/β-Catenin Pathways* , 2010, The Journal of Biological Chemistry.

[139]  T. Kowalski,et al.  Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. , 2010, The Journal of endocrinology.

[140]  D. Murray,et al.  Cholestyramine Reverses Hyperglycemia and Enhances Glucose-Stimulated Glucagon-Like Peptide 1 Release in Zucker Diabetic Fatty Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[141]  J. Rosenstock,et al.  Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[142]  M. Evans,et al.  Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. , 2010, Journal of medicinal chemistry.

[143]  T. Rao,et al.  Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. , 2010, Bioorganic & medicinal chemistry letters.

[144]  H. Chiba,et al.  Colestimide, an anion exchange resin agent, can decrease the number of LDL particles without affecting their size in patients with hyperlipidemia. , 2010, Journal of cardiology.

[145]  F. Pattou,et al.  The nuclear receptor FXR is expressed in pancreatic β‐cells and protects human islets from lipotoxicity , 2010, FEBS letters.

[146]  S. Schwartz,et al.  The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. , 2010, Metabolic syndrome and related disorders.

[147]  Michael Müller,et al.  Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor– and liver X receptorα–controlled metabolic pathways in mice , 2010, Hepatology.

[148]  J. Holst,et al.  Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[149]  D. Häussinger,et al.  The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes , 2010, Biological chemistry.

[150]  J. Auwerx,et al.  Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. , 2010, Journal of medicinal chemistry.

[151]  K. Kostner,et al.  Farnesoid X receptor represses hepatic human APOA gene expression. , 2011, The Journal of clinical investigation.

[152]  G. Bifulco,et al.  The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis , 2011, PloS one.

[153]  M. Orešič,et al.  Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.

[154]  A. Baghdasaryan,et al.  Dual farnesoid X receptor/TGR5 agonist INT‐767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO  3− output , 2011, Hepatology.

[155]  P. Libby,et al.  Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.

[156]  K. Einarsson,et al.  Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism , 2011, European Journal of Clinical Pharmacology.

[157]  S. Turner,et al.  Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study , 2012, Diabetologia.

[158]  J. Auwerx,et al.  TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. , 2011, Cell metabolism.

[159]  J. Auwerx,et al.  Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure* , 2011, The Journal of Biological Chemistry.

[160]  S. Kliewer,et al.  The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. , 2011, Molecular endocrinology.

[161]  Shawn P Williams,et al.  Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. , 2011, Bioorganic & medicinal chemistry letters.

[162]  J. Auwerx,et al.  The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. , 2011, Journal of hepatology.

[163]  A. Gerding,et al.  Bile Acid Sequestration Reduces Plasma Glucose Levels in db/db Mice by Increasing Its Metabolic Clearance Rate , 2011, PloS one.

[164]  S. Grundy,et al.  Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. , 2011, The American journal of cardiology.

[165]  H. Bays.  Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[166]  Hans Richter,et al.  Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor , 2011, Journal of Lipid Research.

[167]  S. Mudaliar,et al.  Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus , 2012, Diabetes, obesity & metabolism.

[168]  B. Staels,et al.  Bile Acid Sequestrants and the Treatment of Type 2 Diabetes Mellitus , 2012, Drugs.

[169]  Yanqiao Zhang,et al.  Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. , 2012, Molecular endocrinology.